10-Q: Strata Skin Sciences Reports First Quarter 2024 Results Amidst Market Challenges

Strata Skin Sciences reported a net loss of $3.368 million for the first quarter of 2024, impacted by lower revenues and increased costs.

Summary

• Strata Skin Sciences reported a net loss of $3.368 million for the first quarter of 2024, compared to a net loss of $2.835 million in the same period of 2023.
• Revenue decreased to $6.754 million from $7.567 million year-over-year.
• The company experienced a decrease in gross profit to $3.080 million from $4.388 million year-over-year, with a gross profit margin of 45.6% compared to 58.0% in the prior year.
• Operating expenses were $5.969 million, down from $6.974 million in the first quarter of 2023.
• The company had 907 XTRAC systems placed in dermatologists' offices in the U.S. as of March 31, 2024, a decrease from 923 at the end of 2023.
• The company is facing challenges including the impact of the COVID-19 pandemic, the Russia-Ukraine war, and the Israel-Hamas conflict on its operations and supply chains.
• The company is also dealing with ongoing sales tax assessments from New York and California totaling $3.9 million.
• The company plans a 1-for-10 reverse stock split on June 6, 2024, to comply with Nasdaq's minimum bid price requirement.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to decreased revenue, increased losses, and ongoing financial and operational challenges. The need for a reverse stock split and the high interest rate on debt further contribute to the negative outlook.

Positives

• Operating expenses decreased to $5.969 million in Q1 2024 from $6.974 million in Q1 2023.
• Engineering and product development expenses decreased to $241 thousand in Q1 2024 from $315 thousand in Q1 2023.
• The company has been resourceful in maintaining its gas supply despite the Russia-Ukraine war.
• The company settled a PAGA class action lawsuit for $106 thousand.

Negatives

• The company experienced a decrease in revenue and gross profit.
• The number of XTRAC systems placed in the U.S. decreased.
• The company is facing significant sales tax assessments.
• The company's net loss increased year-over-year.
• The company's cash and cash equivalents decreased to $5.237 million from $6.784 million at the end of 2023.
• The company's working capital decreased to $651 thousand from $3.369 million at the end of 2023.

Risks

• The company is facing ongoing challenges from the COVID-19 pandemic, the Russia-Ukraine war, and the Israel-Hamas conflict.
• Supply chain disruptions and rising interest rates could impact the company's ability to access financing.
• The company is subject to sales tax audits and assessments, with a potential liability of $3.9 million.
• The company's ability to maintain its Nasdaq listing is at risk, requiring a reverse stock split.
• The company's debt has a high interest rate of 13.94%.

Future Outlook

The company believes that its cash and cash equivalents, combined with anticipated revenues and operating expense management, will be sufficient to satisfy its liquidity requirements for at least the next 12 months. However, market conditions and other factors could interfere with the company's ability to access financing.

Management Comments

• Management believes that several factors have an impact on the prescribed use of XTRAC treatments for psoriasis and vitiligo patients.
• Management believes that there is a lack of awareness of the positive effects of XTRAC treatments among both sufferers and providers.
• Management believes that the treatment regimen, which can sometimes require up to 12 or more treatments, has limited XTRAC use to certain patient populations.
• The company's strategy going forward is to increase its direct-to-patient program for XTRAC advertising in the United States.

Industry Context

The medical technology industry is facing challenges due to the COVID-19 pandemic, supply chain disruptions, and geopolitical conflicts. Strata Skin Sciences is experiencing these challenges, impacting its financial performance and operations. The company is also facing competition in the dermatology market, requiring it to innovate and adapt to changing market conditions.

Comparison to Industry Standards

• Strata's gross profit margin of 45.6% is lower than some of its competitors in the medical device industry, which often have margins above 60%.
• Companies like InMode and Cutera, which also focus on aesthetic and dermatological devices, have reported higher revenue growth and profitability in recent quarters.
• Strata's reliance on recurring revenue from placed devices is similar to business models used by companies like Cynosure, but Strata's recurring revenue is not growing as quickly.
• The company's challenges with sales tax assessments are not unique, as many medical device companies face complex tax regulations across different states and countries.
• The planned reverse stock split is a common strategy for companies facing delisting from major exchanges, but it can also signal financial distress.

Legal Proceedings

• The company is involved in ongoing sales tax disputes with New York and California, with assessments totaling $3.9 million.
• The company settled a PAGA class action lawsuit for $106 thousand.

Stakeholder Impact

• Shareholders will experience dilution if the company raises additional equity capital.
• Shareholders will be impacted by the reverse stock split.
• Employees may be affected by cost-cutting measures.
• Customers may be impacted by supply chain disruptions.
• Creditors are exposed to the company's financial risks.

Next Steps

• The company plans to increase its direct-to-patient advertising program for XTRAC in the United States.
• The company will effect a 1-for-10 reverse stock split on June 6, 2024, unless its stock price meets Nasdaq's minimum bid price requirement.
• The company will continue to manage its operating expenses and monitor the impact of external factors on its business.

Key Dates

Keywords

XTRAC, TheraClear, dermatology, laser, revenue, net loss, gross profit, operating expenses, sales tax, reverse stock split, medical technology, financial results